CompoundSummaryTable
From ToxBankWiki
CompoundSummaryTable
Hepatotoxins | ||||
---|---|---|---|---|
Toxicant | Inititiating Mechanism | Adverse Event of Interest | Wiki Table | Product Source |
Reactive Molecules | ||||
Acetaminophen | Non-selective thiol reagent | Cytotoxicity | Yes | A7085 |
Iodoacetamide | Selective thiol reagent | Cytotoxicity | Yes | I1149 |
Allyl alcohol | Selective thiol reagent, energy source | Fibrosis | Yes | 240532 |
DMNQ | Redox cycling | Cytotoxixity | Yes | D5439 |
CCl4 | Free radical generator | Steatosis, fibrosis | Yes | 02671 |
Aflatoxin B1 | Lysine reagent | Apoptosis | Yes | A6636 |
Mitochondrial Disruption | ||||
Antimycin A | Mitochondrial disruption, ROS | Cytotoxicity | No | |
Oligomycin A | Inhibition of complex V | Cytotoxixity | Yes | 4110 |
Rotenone | Inhibition of complex I | Cytotoxixity | Yes | 45656 |
FCCP | Proton gradient uncoupler | Cytotoxixity | Yes | 0453 |
Promiscuous Binding | ||||
Valproic Acid | Membrane disruption, inhibition of fatty acid beta-oxidation | Steatosis | Yes | P4543 |
Chlorpromazine | Membrane disruption | Cholestasis | Yes | 31679 |
Amiodarone | Phospholipid binding, membrane disruption, inhibition of fatty acid beta-oxidation | Phospholipidosis, steatosis | Yes | 4095 |
Selective Binding | ||||
Methotrexate | Antifolate | Fibrosis | Yes | M8407 |
Bosentan | BSEP inhibitor | Cholestasis | Yes | SRP02325b |
Dirlotapide | Microsomal triglyceride transport inhibitor | Steatosis | Yes | |
Fluoxetine | Phospholipid binding | Phospholipidosis | Yes | 34012 |
Hygromycin B | Ribosome inhibitor | Cytotoxicity | Yes | ant-hg-10p |
Nuclear Hormone Receptor Ligads | ||||
TO901317 | Dual LXR-PXR agonist | Steatosis | Yes | T2320 |
Rifampicin | PXR agonist | Negative control, steatosis | Yes | R3501 |
WY14643 | PPAR-α agonist | Lipid metabolism disruption, proliferation | No | |
β-Naphthoflavone | AhR agonist | Lipid metabolism disruption | No | |
Tamoxifen | ER modulator | Epigenetics | Yes | T5648 |
Nephrotoxins | ||||
KBrO3 | Strong oxidizing agent | Cytotoxicity | Yes | 60085 |
Ochratoxin A | Cytoskeleton disruption | Epigenetics | Yes | O1877 |
Cardiotoxins | ||||
Doxorubicin | Topoisomerase inhibitor, redox cycling | Repeated dose organ failure | Yes | 44583 |
Antimycin A | Mitochondrial disruption, ROS | Cytotoxicity | No | |
E4031 | hERG antagonist | Torsade de Pointes | Yes | |
Carbachol | Cholinergic agonist | Cell phenotyping | Yes | |
Isoproterenol | Adrenergic agonist | Cell phenotyping | No | |
Nifedipine | L-type Ca channel antagonist | Cell phenotyping | No | |
Neurotoxins | ||||
Naphthol AS-E Phosphate | CREB inhibitor | Mechanistic standard | ||
Forskolin | CREB activator | Mechanistic standard | No | |
DAPT | Notch1 inhibitor | Mechanistic standard | No | |
Rapamycin | mTOR inhibitor | Mechanistic standard | No | |
GSK2334470 | PDK1 inhibitor | Mechanistic standard | No | |
Akt 1/2 inhibitor | AKT kinase nhibitor | Mechanistic standard | No | |
Nocodazole | Inhibition of neurite outgrowth | No | ||
U0126 | Inhibition of neurite outgrowth | No | ||
Acrylamide | Inhibition of neurite outgrowth | No | ||
Propofol | Inhibition of synaptogenesis | No | ||
Lead(II) Chloride | Inhibition of synaptogenesis | No | ||
Chlorpyrifos | Organophosphate acetylcholinesterase inhibitor | Affecting cAMP signalling (CREB) | No | |
Diazanon | Organophosphate acetylcholinesterase inhibitor | Affecting cAMP signalling (CREB) | No | |
Dieldrin | Affecting cAMP signalling (CREB) | No | ||
Ni2+ | Affecting cAMP signalling (CREB) | No | ||
Tributyltin (TBT) | Affecting cAMP signalling (CREB) | No | ||
Trimethyltin (TMT) | Affecting cAMP signalling (CREB) | No | ||
PCB 153 | Affecting Notch signalling | No | ||
PCB 180 | Affecting Notch signalling | No | ||
Glutamate | Affecting PDK1/Akt /mTOR signalling | No | ||
Generic Negative Controls | ||||
D-Mannitol | NA | NA | No |